Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.590

+3.6%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: enzyme	5/18/2009 11:49:21 AM
	Read Replies (1) of 368

Phase 2 interm results. SB509 turns DN blocked nerves back on! Here's the title to the abstract that Sangamo is presenting at ADA June 7th. This should reverse their phase 2 failure! Reappearance of Nerve Potentials in Severe Diabetic Peripheral Neuropathy Patients with Unmeasurable Nerve Conduction Using Vascular Endothelial Growth Factor Zinc Finger Protein Activator (SB-509): Interim Phase 2 Results (SB-509-0701 Study) Abstract No: 243-OR Presented During: Neuropathy Abstract Type: Oral Author(s): ELY BENAIM, SCOTT HAMILTON, KAYE SPRATT, MARTY GIEDLIN, HEIDI KIM, DALE ANDO, SANGAMO DN STUDY GROUP Location(s): Richmond, CA The contents of this abstract are not available for public viewing at this time. Abstracts will be made available on Fri, 5/22 at 12:00 AM. Abstracts selected for General Posters or Publish Only are embargoed from the time of submission until 10:00 a.m. Central Daylight Time (11:00 AM EDT), Saturday, June 6, 2009. Abstracts selected for Oral Presentation are embargoed from submission until the time of presentation. Enzyme

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next